GPC3 and hepatocellular carcinoma: (10) firstly published a phase I trial of CAR-GPC-3 T-cell therapy in patients with advanced HCC, and their results demonstrated the initial safety profile and early signs of antitumor activity of CAR-GPC-3 T cells.